Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis: A comparative study with CA 19-9

Cancer

Volumn 89, Issue 1, 2000, Pages 83-88

  Slesak, Barbara ^a   Harlozinska Szmyrka, Antonina ^a   Knast, Witold ^a   Sedlaczek, Pawel ^a   Van Dalen, Arie ^b   Einarsson, Roland ^c,d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Institute of Tumor Marker Oncology   (Netherlands)

^c IDL Biotech   (Sweden)

^d Glucox Biotech AB   (Sweden)

Author keywords

CA 19 9; Chronic pancreatitis; Differential diagnosis; Pancreatic carcinoma; Tissue polypeptide specific antigen (TPS); Tumor markers

Indexed keywords

TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CHRONIC PANCREATITIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ADULT; AGED; CA-19-9 ANTIGEN; CARCINOMA; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0034234640     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J     Document Type: Article

References (23)

1. Meller-Höcker J. Pathomorphology and morphological diagnosis of exocrine pancreatic carcinomas. Diagn Oncol 1993;3:133-45.
2. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-70.
3. Safi F, Beger HG, Bittner R, Büchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986;57:779-83.
4. Lamerz R. General remarks on exocrine pancreatic cancer. Diagn Oncol 1993;3:128-32.
5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
6. Grem J. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 1997;9:380-7.
7. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P. Behavior of tumor markers CA 19-9, CA 195, CAM 43, CA 242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993;39:420-3.
8. Ventrucci M, Ubalducci GM, Cipolla A, Panella MA, Ligabue A. Serum CA 242: the search for a valid marker of pancreatic cancer. Clin Chem Lab Med 1998;36:179-84.
9. Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, et al. Comparative study of CA 242 and CA 19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6.
10. Sperti C, Pasquali C, Guolo P, Polverosi R, Liessi G, Pedrozzoli S. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer 1996;78:237-43.
11. Gansauge F, Gansauge S, Parker N, Beger MI, Poch B, Link KH, et al. CAM 17.1 - A new diagnostic marker in pancreatic cancer. Br J Cancer 1996;74:1997-2002.
12. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349: 389-92.
13. Rydlander L, Ziegler E, Bergman T, Schöberl E, Steiner G, Bergman AC, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996;241:309-14.
14. Björklund B. A conceptual approach to tumor antigen in the past and in the future with special reference to TPS. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, editors. Updating on tumor markers in tissues and in biological fluids. Turin: Edizioni Minerva Medica, 1993:651-69.
15. Plebani M, Basso D, Del Favero G, Ferrara C, Meggiato T, Fogar P, et al. Clincal utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. Oncology 1993;50:436-40.
16. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma. Tumor Biol 1994;15:52-60.
17. Ito T, Migita Y, Nakano I, Kimura J, Furukawa M, Ryu G, et al. A clinical evaluation of tissue polypeptide specific antigen (TPSA) in pancreatic cancer patients. Rinsho Kenkyu 1995;72:224-8.
18. Slesak B, Harlozinska A, Knast W, Sedlaczek P, Einarsson R. Clinical utility of TPS (tissue polypeptide specific antigen) in differential diagnosis of chronic pancreatitis and pancreatic cancer. Nowotwory 1997;47:689-700.
19. Sobin LH, Hermanek P, Hutter RVP. TNM classification of malignant tumors. 4th edition. Geneva: International Union Against Cancer, 1987.
20. Zweig MH, Campell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
21. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9.
22. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110: 704-9.
23. Kornek G, Schenk T, Raderer M, Djavarnmad M, Scheithauer W. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 1995;71:182-5.